CRISPR Therapeutics (CRSP) has caught investor attention after becoming the first gene editing peer to generate commercial revenue from its approved therapy Casgevy, supported by Vertex Pharmaceuticals and a sizable cash cushion for upcoming trials.

CRISPR Therapeutics’ recent news on Casgevy and upcoming trial milestones comes after a sharp 1 year total shareholder return of 51.59%, even as the 30 day share price return of 14.73% and 90 day share price return of 7.92% suggest some momentum has cooled in the short term.

If this kind of gene editing story has your attention, it may be a good time to widen your search with other healthcare names using our screener for 37 healthcare AI stocks

With CRISPR shares down 14.73% over 30 days but still up 51.59% over 1 year and trading at a sizable discount to the average analyst price target, investors may question whether this is a fresh entry point or whether the market is already incorporating years of future growth.

Preferred Price to Book of 2.5x: Is it justified?

CRISPR Therapeutics last closed at $49.51, while its price to book ratio of 2.5x screens a little richer than the broader US biotech peer group but well below its closer peer set.

The P/B ratio compares the company’s market value to its book value, which is a useful cross check for asset heavy or early stage biotech names that do not yet generate meaningful earnings. For CRISPR Therapeutics, this 2.5x figure sits against an industry average of 2.3x, which indicates that the market is placing a slightly higher value on each dollar of net assets relative to the wider US Biotechs industry.

At the same time, the stock is described as good value against a peer average P/B of 9.2x and is trading 73.9% below the SWS DCF model estimate of future cash flow value of $189.74. Together, these figures indicate that investors are paying a modest premium to the sector average book value multiple, while the company-specific fair value model points to a level the market might move towards if future revenue forecasts and cash flows occur as modeled.

Result: Price to book of 2.5x (ABOUT RIGHT)

However, the story can change quickly if Casgevy uptake disappoints or if key trials across the broader pipeline encounter delays, safety issues, or mixed data.

Another View: SWS DCF Versus The 2.5x P/B Tag

While the 2.5x P/B ratio suggests CRISPR Therapeutics is only slightly more expensive than the wider US Biotechs group, the SWS DCF model points to a very different picture, with an estimated future cash flow value of $189.74 versus a share price of $49.51. If the market ever moved closer to that DCF output, the gap between the two yardsticks would matter a lot. This raises an important question: which one should investors consider more relevant for a high risk, early stage business like this?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 62 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals across valuation models and sentiment, it helps to review the details yourself and decide quickly where you stand on the stock. To see both sides of the story in one place, review the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at a single stock. Use targeted tools to uncover opportunities that fit your goals.

• Target potential value opportunities before they get crowded by scanning 62 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
• Prioritise durability in your portfolio by reviewing 67 resilient stocks with low risk scores that score well on resilience and business risk.
• Get ahead of the crowd by tracking screener containing 25 high quality undiscovered gems that pair solid fundamentals with relatively low market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.